Designer Benzodiazepines: A Review of Toxicology and Public Health Risks
Abstract
:1. Introduction
2. Results
2.1. Adinazolam
2.2. Clonazolam
2.3. Deschloroetizolam
2.4. Diclazepam
2.5. Etizolam
2.6. Flualprazolam
2.7. Flubromazepam
2.8. Flubromazolam
2.9. Meclonazepam
2.10. Phenazepam and 3-Hydroxyphenazepam
2.11. Pyrazolam
3. Discussion
4. Materials and Methods
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Huppertz, L.M.; Bisel, P.; Westphal, F.; Franz, F.; Auwärter, V.; Moosmann, B. Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites. Forensic Toxicol. 2015, 33, 388–395. [Google Scholar] [CrossRef]
- Álvarez-Freire, I.; Brunetti, P.; Cabarcos-Fernández, P.; Fernández-Liste, A.; Tabernero-Duque, M.J.; Bermejo-Barrera, A.M. Determination of benzodiazepines in pericardial fluid by gas chromatography–mass spectrometry. J. Pharm. Biomed. Anal. 2018, 159, 45–52. [Google Scholar] [CrossRef]
- Pichini, S.; Papaseit, E.; Joya, X.; Vall, O.; Farré, M.; Garcia-Algar, O.; De Latorre, R. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther. Drug Monit. 2009, 31, 283–318. [Google Scholar] [CrossRef] [PubMed]
- Ansseau, M.; Doumont, A.; Thiry, D.; von Frenckell, R.; Collard, J. Initial study of methylclonazepam in generalized anxiety disorder—Evidence for greater power in the cross-over design. Psychopharmacology 1985, 87, 130–135. [Google Scholar] [CrossRef] [PubMed]
- Katselou, M.; Papoutsis, I.; Nikolaou, P.; Spiliopoulou, C.; Athanaselis, S. Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam. Forensic Toxicol. 2017, 35, 1–10. [Google Scholar] [CrossRef] [Green Version]
- Tamama, K.; Lynch, M.J. Newly emerging drugs of abuse. Handb. Exp. Pharmacol. 2020, 258, 463–502. [Google Scholar] [CrossRef]
- Hayhoe, B.; Lee-Davey, J. Tackling benzodiazepine misuse. BMJ 2018, 362, k3208. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Twyman, R.E.; Rogers, C.J.; Macdonald, R.L. Differential regulation of γ-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann. Neurol. 1989, 25, 213–220. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sigel, E.; Ernst, M. The Benzodiazepine Binding Sites of GABAA Receptors. Trends Pharmacol. Sci. 2018, 39, 659–671. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.J.; Gharpure, A.; Teng, J.; Zhuang, Y.; Howard, R.J.; Zhu, S.; Noviello, C.M.; Walsh, R.M.; Lindahl, E.; Hibbs, R.E. Shared structural mechanisms of general anaesthetics and benzodiazepines. Nature 2020, 585, 303–308. [Google Scholar] [CrossRef]
- Guina, J.; Merrill, B. Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives. J. Clin. Med. 2018, 7, 17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Batlle, E.; Lizano, E.; Viñas, M.; Dolors Pujol, M. 1,4-Benzodiazepines and New Derivatives: Description, Analysis, and Organic Synthesis. In Medicinal Chemistry; Vašková, J., Vaško, L., Eds.; IntechOpen: London, UK, 2019; pp. 63–90. [Google Scholar]
- Bliding, Å. The abuse potential of benzodiazepines with special reference to oxazepam. Acta Psychiatr. Scand. 1978, 58, 111–116. [Google Scholar] [CrossRef]
- Kaufmann, C.N.; Spira, A.P.; Depp, C.A.; Mojtabai, R. Long-term use of benzodiazepines and nonbenzodiazepine hypnotics, 1999–2014. Psychiatr. Serv. 2018, 69, 235–238. [Google Scholar] [CrossRef]
- Ayd, F.J., Jr. Benzodiazepines: Dependence and withdrawal. JAMA 1979, 242, 1401–1402. [Google Scholar] [CrossRef]
- Lader, M.H. Limitations on the use of benzodiazepines in anxiety and insomnia: Are they justified? Eur. Neuropsychopharmacol. 1999, 9, S399–S405. [Google Scholar] [CrossRef]
- Mehdi, T. Benzodiazepines revisited. BJMP 2012, 5, a501. [Google Scholar]
- Ashton, H. The diagnosis and management of benzodiazepine dependence. Curr. Opin. Psychiatry 2005, 18, 249–255. [Google Scholar] [CrossRef] [PubMed]
- Wick, J.Y. The history of benzodiazepines. Consult. Pharm. 2013, 28, 538–548. [Google Scholar] [CrossRef]
- Khan, I. International regulation of benzodiazepine. Prog. Neuro Psychopharmacol. Biol. Psychiatry 1992, 16, 9–16. [Google Scholar] [CrossRef]
- Pond, S.M.; Tong, T.G.; Benowitz, N.L.; Jacob, P., 3rd. Lack of effect of diazepam on methadone metabolism in methadone-maintained addicts. Clin. Psychopharmacol. Ther. 1982, 31, 139–143. [Google Scholar] [CrossRef]
- Woody, G.E.; O’brien, C.P.; Greenstein, R. Misuse and abuse of diazepam: An increasingly common medical problem. Int. J. Addict. 1975, 10, 843–848. [Google Scholar] [CrossRef]
- Lader, M. History of benzodiazepine dependence. J. Subst. Abuse Treat. 1991, 8, 53–59. [Google Scholar] [CrossRef]
- Barnas, C.; Rossmann, M.; Roessler, H.; Riemer, Y.; Fleischhacker, W. Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: Familiarity and preference. Clin. Neuropharmacol. 1992, 15 (Suppl. 1), 110A–111A. [Google Scholar] [CrossRef]
- Forsyth, A.J.M.; Farquhar, D.; Gemmell, M.; Shewan, D.; Davies, J.B. The dual use of opioids and temazepam by drug injectors in Glasgow (Scotland). Drug Alcohol Depend. 1993, 32, 277–280. [Google Scholar] [CrossRef]
- Gautam, L.; Sharratt, S.D.; Cole, M.D. Drug facilitated sexual assault: Detection and stability of benzodiazepines in spiked drinks using gas chromatography-mass spectrometry. PLoS ONE 2014, 9, e89031. [Google Scholar] [CrossRef]
- Agarwal, S.D.; Landon, B.E. Patterns in Outpatient Benzodiazepine Prescribing in the United States. JAMA Netw. Open 2019, 2, e187399. [Google Scholar] [CrossRef] [Green Version]
- Horsfall, J.T.; Sprague, J.E. The Pharmacology and Toxicology of the ‘Holy Trinity’. Basic Clin. Pharmacol. Toxicol. 2017, 120, 115–119. [Google Scholar] [CrossRef]
- Schmitz, A. Benzodiazepines: The time for systematic change is now. Addiction 2021, 116, 219–221. [Google Scholar] [CrossRef] [Green Version]
- UNODC. Global SMART Update Volume 18. Non-Medical Use of Benzodiazepines: A Growing Threat to Public Health? Available online: https://www.unodc.org/documents/scientific/Global_SMART_Update_2017_Vol_18.pdf (accessed on 8 December 2020).
- EMCDDA. The Misuse of Benzodiazepines among High-Risk Opioid Users in Europe. Available online: http://www.emcdda.europa.eu/system/files/publications/2733/Misuse of benzos_POD2015.pdf (accessed on 1 December 2020).
- Zawilska, J.B.; Wojcieszak, J. An expanding world of new psychoactive substances-designer benzodiazepines. Neurotoxicology 2019, 73, 8–16. [Google Scholar] [CrossRef]
- Vårdal, L.; Wong, G.; Øiestad, Å.M.L.; Pedersen-Bjergaard, S.; Gjelstad, A.; Øiestad, E.L. Rapid determination of designer benzodiazepines, benzodiazepines, and Z-hypnotics in whole blood using parallel artificial liquid membrane extraction and UHPLC-MS/MS. Anal. Bioanal. Chem. 2018, 410, 4967–4978. [Google Scholar] [CrossRef]
- Gheddar, L.; Ricaut, F.X.; Ameline, A.; Brucato, N.; Tsang, R.; Leavesley, M.; Raul, J.S.; Kintz, P. Testing for Betel Nut Alkaloids in Hair of Papuans Abusers using UPLC-MS/MS and UPLC-Q-Tof-MS. J. Anal. Toxicol. 2020, 44, 41–48. [Google Scholar] [CrossRef]
- Fryer, R.I.; Schmidt, R.A.; Sternbach, L.H. Quinazolines and 1,4-benzodiazepines XVII. Synthesis of 1,3-dihydro-5-pyridyl-2H-1,4-benzodiazepine derivatives. J. Pharm. Sci. 1964, 53, 264–268. [Google Scholar] [CrossRef] [PubMed]
- Sternbach, L.H.; Fryer, R.I.; Keller, O.; Metlesics, W.; Sach, G.; Steiger, N. Quinazolines and 1,4-Benzodiazepines. X.’ Nitro-Substituted 5-Phenyl-1,4-benzodiazepine Derivatives. J. Med. Chem. 1963, 6, 261–265. [Google Scholar] [CrossRef] [PubMed]
- Olkkola, K.T.; Ahonen, J. Midazolam and other benzodiazepines. Handb. Exp. Pharmacol. 2008, 182, 335–360. [Google Scholar] [CrossRef]
- Atkin, T.; Comai, S.; Gobbi, G. Drugs for insomnia beyond benzodiazepines: Pharmacology, clinical applications, and discovery. Pharmacol. Rev. 2018, 70, 197–245. [Google Scholar] [CrossRef]
- Greenblatt, H.K.; Greenblatt, D.J. Designer Benzodiazepines: A Review of Published Data and Public Health Significance. Clin. Pharmacol. Drug Dev. 2019, 8, 266–269. [Google Scholar] [CrossRef]
- Waters, L.; Manchester, K.R.; Maskell, P.D.; Haegeman, C.; Haider, S. The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines. Sci. Justice 2018, 58, 219–225. [Google Scholar] [CrossRef] [Green Version]
- El Balkhi, S.; Monchaud, C.; Herault, F.; Géniaux, H.; Saint-Marcoux, F. Designer benzodiazepines’ pharmacological effects and potencies: How to find the information. J. Psychopharmacol. 2020, 34, 1021–1029. [Google Scholar] [CrossRef]
- Muzaale, A.D.; Daubresse, M.; Bae, S.; Chu, N.M.; Lentine, K.L.; Segev, D.L.; McAdams-Demarco, M. Benzodiazepines, codispensed opioids, and mortality among patients initiating long-term in-center hemodialysis. Clin. J. Am. Soc. Nephrol. 2020, 15, 794–804. [Google Scholar] [CrossRef] [PubMed]
- Graddy, R.; Buresh, M.E.; Rastegar, D.A. New and Emerging Illicit Psychoactive Substances. Med. Clin. N. Am. 2018, 102, 697–714. [Google Scholar] [CrossRef]
- Orsolini, L.; Corkery, J.M.; Chiappini, S.; Guirguis, A.; Vento, A.; De Berardis, D.; Papanti, D.; Schifano, F. ‘New/Designer Benzodiazepines’: An Analysis of the Literature and Psychonauts’ Trip Reports. Curr. Neuropharmacol. 2020, 18, 809–837. [Google Scholar] [CrossRef]
- Shapiro, A.P.; Krew, T.S.; Vazirian, M.; Jerry, J.; Sola, C. Novel Ways to Acquire Designer Benzodiazepines: A Case Report and Discussion of the Changing Role of the Internet. Psychosomatics 2019, 60, 625–629. [Google Scholar] [CrossRef]
- Benesch, M.G.K.; Iqbal, S.J. Novel psychoactive substances: Overdose of 3-fluorophenmetrazine (3-FPM) and etizolam in a 33-year-old man. BMJ Case Rep. 2018, 2018, bcr2018224995. [Google Scholar] [CrossRef]
- UNODC. World Drug Report 2019—Booklet 3: Depressants. Available online: https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_3_DEPRESSANTS.pdf (accessed on 18 September 2020).
- Manchester, K.R.; Lomas, E.C.; Waters, L.; Dempsey, F.C.; Maskell, P.D. The emergence of new psychoactive substance (NPS) benzodiazepines: A review. Drug Test. Anal. 2018, 10, 37–53, Erratum in 2018, 10, 392–393, doi:10.1002/dta.2349. [Google Scholar] [CrossRef] [Green Version]
- EMCDDA. Europol 2013 Annual Report on the Implementation of Council Decision 2005/387/JHA. Available online: http://www.emcdda.europa.eu/attachements.cfm/att_229598_EN_TDAN14001ENN.pdf (accessed on 15 December 2020).
- EMCDDA. Europol 2014 Annual Report on the Implementation of Council Decision 2005/387/JHA. Available online: https://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf (accessed on 15 December 2020).
- EMCDDA. Europol 2015 Annual Report on the Implementation of Council Decision 2005/387/JHA. Available online: https://www.emcdda.europa.eu/system/files/publications/2880/TDAS16001ENN.pdf (accessed on 15 December 2020).
- EMCDDA. Europol 2016 Annual Report on the Implementation of Council Decision 2005/387/JHA. Available online: http://www.emcdda.europa.eu/system/files/publications/4724/TDAN17001ENN_PDFWEB.pdf (accessed on 16 December 2020).
- EMCDDA. Europol 2017 Annual Report on the Implementation of Council Decision 2005/387/JHA. Available online: https://www.emcdda.europa.eu/system/files/publications/9282/20183924_TDAN18001ENN_PDF.pdf (accessed on 16 December 2020).
- UNODC. Global Synthetic Drugs Assessment 2020—Regional Overviews. Available online: https://www.unodc.org/documents/scientific/Global_Synthetic_Drugs_Assessment_2020.pdf (accessed on 1 January 2021).
- Bade, R.; Ghetia, M.; White, J.M.; Gerber, C. Determination of prescribed and designer benzodiazepines and metabolites in influent wastewater. Anal. Methods 2020, 12, 3637–3644. [Google Scholar] [CrossRef]
- NSW Government. Public Drug Warnings 2021: Non-Pharmaceutical Grade (Counterfeit) Alprazolam Tablets Containing Etizolam. Available online: https://www.health.nsw.gov.au/aod//public-drug-alerts/Pages/drug-warning-counterfeit-alprazolam.aspx (accessed on 25 April 2021).
- Licata, S.C.; Rowlett, J.K. Abuse and dependence liability of benzodiazepine-type drugs: GABAA receptor modulation and beyond. Pharmacol. Biochem. Behav. 2008, 90, 74–89. [Google Scholar] [CrossRef] [Green Version]
- EMCDDA. Euroean Drug Report 2020: Key Issues. Available online: https://www.emcdda.europa.eu/system/files/publications/13238/TD0420439ENN.pdf (accessed on 15 February 2021).
- NFLIS. Drug 2018 Annual Report. Available online: https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLIS-Drug-AR2018.pdf (accessed on 24 February 2021).
- NFLIS. Drug 2019 Annual Report. Available online: https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLIS-Drug-AR2019.pdf (accessed on 24 February 2021).
- DEA. Emerging Threat Report: Annual 2018. Available online: https://cesar.umd.edu/sites/cesar.umd.edu/files/pubs/DEA-Emerging-Threat-Report-2018-Annual.pdf (accessed on 24 February 2021).
- DEA. Emerging Threat Report: Annual 2019. Available online: https://cesar.umd.edu/sites/cesar.umd.edu/files/pubs/DEA-Emerging-Threat-Report-2019-Annual.pdf (accessed on 23 February 2021).
- UNODC. World Drug Report 2019—Booklet 5: Cannabis and Hallucinogens. Available online: https://wdr.unodc.org/wdr2019/prelaunch/WDR19_Booklet_5_CANNABIS_HALLUCINOGENS.pdf (accessed on 18 September 2020).
- EMCDDA. Euroean Drug Report 2020: Trends and Developments. Available online: https://www.emcdda.europa.eu/system/files/publications/13236/TDAT20001ENN_web.pdf (accessed on 3 March 2021).
- Zaami, S.; Marinelli, E.; Varì, M.R. New Trends of Substance Abuse During COVID-19 Pandemic: An International Perspective. Front. Psychiatry 2020, 11, 700. [Google Scholar] [CrossRef]
- Del Rio, A.; Graziano, S.; Tittarelli, R.; Umani-Ronchi, F. Letter Increasing diversion of prescribed benzodiazepines and Z-drugs to new psychoactive substances. Clin. Ter. 2021, 172, 116–118. [Google Scholar] [CrossRef]
- Brunetti, P.; Pirani, F.; Carlier, J.; Giorgetti, R.; Busardò, F.P.; Lo Faro, A.F. A 2017–2019 Update on Acute Intoxications and Fatalities from Illicit Fentanyl and Analogs. J. Anal. Toxicol. 2020, bkaa115. [Google Scholar] [CrossRef]
- EMCDDA. Trendspotter Briefing: Impact of COVID-19 on Patterns of Drug Use and Drug-Related Harms in Europe. Available online: https://www.emcdda.europa.eu/system/files/publications/13130/EMCDDA-Trendspotter-Covid-19-Wave-2_1.pdf (accessed on 26 February 2021).
- CFSRE. NPS Benzodiazepines in the United States—Trend Report: Q2. 2020. Available online: https://www.npsdiscovery.org/wp-content/uploads/2020/07/2020-Q2_NPS-Benzodiazepines_Trend-Report_rev.pdf (accessed on 21 January 2021).
- Herrera-Gómez, F.; Garciá-Mingo, M.; Álvarez, F.J. Benzodiazepines in the oral fluid of Spanish drivers. Subst. Abus. Treat. Prev. Policy 2020, 15, 18. [Google Scholar] [CrossRef] [PubMed]
- Rohrig, T.P.; Osawa, K.A.; Baird, T.R.; Youso, K.B. Driving Impairment Cases Involving Etizolam and Flubromazolam. J. Anal. Toxicol. 2021, 45, 93–98. [Google Scholar] [CrossRef]
- UNODC. Current NPS Threats Volume III. Available online: https://www.unodc.org/documents/scientific/Current_NPS_Threats_Vol.3.pdf (accessed on 25 March 2021).
- UNODC. Early Warning Advisory: List of Announcements. Available online: https://www.unodc.org/LSS/Announcement?type=NPS (accessed on 25 April 2021).
- Bäckberg, M.; Pettersson Bergstrand, M.; Beck, O.; Helander, A. Occurrence and time course of NPS benzodiazepines in Sweden–results from intoxication cases in the STRIDA project. Clin. Toxicol. 2019, 57, 203–212. [Google Scholar] [CrossRef] [PubMed]
- Nowak, K.; Szpot, P.; Zawadzki, M. Fatal intoxication with U-47700 in combination with other NPS (N-ethylhexedrone, adinazolam, 4-CIC, 4-CMC) confirmed by identification and quantification in autopsy specimens and evidences. Forensic Toxicol. 2021. [Google Scholar] [CrossRef]
- Ghazi, M.A.; Mohmand, M. Co-occurring Addiction of Synthetic Benzodiazepine Clonazolam and Propylhexedrine presenting as Acute Brief Psychosis. J. Addict. Med. Ther. 2017, 5, 1037. [Google Scholar]
- Murphy, L.; Melamed, J.; Gerona, R.; Hendrickson, R.G. Clonazolam: A novel liquid benzodiazepine. Toxicol. Commun. 2019, 3, 75–78. [Google Scholar] [CrossRef] [Green Version]
- Židková, M.; Horsley, R.; Hloch, O.; Hložek, T. Near-fatal Intoxication with the “New” Synthetic Opioid U-47700: The First Reported Case in the Czech Republic. J. Forensic Sci. 2019, 64, 647–650. [Google Scholar] [CrossRef] [PubMed]
- Van Wijk, X.M.R.; Yun, C.; Hooshfar, S.; Arens, A.M.; Lung, D.; Wu, A.H.B.; Lynch, K.L. A liquid-chromatography high-resolution mass spectrometry method for non-FDA approved benzodiazepines. J. Anal. Toxicol. 2019, 43, 316–320. [Google Scholar] [CrossRef]
- Sommerfeld-Klatta, K.; Łukasik-Głębocka, M.; Teżyk, A.; Panieński, P.; Żaba, C.; Zielińska-Psuja, B. Clonazolam a new designer benzodiazepine intoxication confirmed by blood concentration. Forensic Sci. Int. 2020, 310, 110237. [Google Scholar] [CrossRef]
- El Balkhi, S.; Chaslot, M.; Picard, N.; Dulaurent, S.; Delage, M.; Mathieu, O.; Saint-Marcoux, F. Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer. Int. J. Legal Med. 2017, 131, 979–988. [Google Scholar] [CrossRef] [PubMed]
- Ameline, A.; Arbouche, N.; Raul, J.S.; Kintz, P. Documentation of a little-studied designer benzodiazepine after a controlled single administration: II. Concentration profile of deschloroetizolam in Saliva. Ther. Drug Monit. 2018, 40, 759–761. [Google Scholar] [CrossRef]
- Gerace, E.; Bovetto, E.; Di Corcia, D.; Vincenti, M.; Salomone, A. A Case of Nonfatal Intoxication Associated with the Recreational use of Diphenidine. J. Forensic Sci. 2017, 62, 1107–1111. [Google Scholar] [CrossRef]
- Runnstrom, M.; Kalra, S.S.; Lascano, J.; Patel, D.C. Overdose from designer benzodiazepine Diclazepam. QJM 2020, 113, 122–124. [Google Scholar] [CrossRef]
- Høiseth, G.; Tuv, S.S.; Karinen, R. Blood concentrations of new designer benzodiazepines in forensic cases. Forensic Sci. Int. 2016, 268, 35–38. [Google Scholar] [CrossRef]
- Heide, G.; Høiseth, G.; Middelkoop, G.; Øiestad, Å.M.L. Blood concentrations of designer benzodiazepines: Relation to impairment and findings in forensic cases. J. Anal. Toxicol. 2020, 44, 905–914. [Google Scholar] [CrossRef]
- Partridge, E.; Trobbiani, S.; Stockham, P.; Charlwood, C.; Kostakis, C. A Case Study Involving U-47700, Diclazepam and Flubromazepam—Application of Retrospective Analysis of HRMS Data. J. Anal. Toxicol. 2018, 42, 655–660. [Google Scholar] [CrossRef]
- O’Connell, C.W.; Sadler, C.A.; Tolia, V.M.; Ly, B.T.; Saitman, A.M.; Fitzgerald, R.L. Overdose of etizolam: The abuse and rise of a benzodiazepine analog. Ann. Emerg. Med. 2015, 65, 465–466. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Love, J.S.; Thompson, J.A.; Horowitz, B.Z. “Pressed” Etizolam. J. Pediatr. 2021, 232, 303–304. [Google Scholar] [CrossRef]
- Gupta, S.; Garg, B. A case of etizolam dependence. Indian J. Pharmacol. 2014, 46, 655–656. [Google Scholar] [CrossRef]
- Banerjee, D. Etizolam withdrawal catatonia: The first case report. Asian J. Psychiatr. 2018, 37, 32–33. [Google Scholar] [CrossRef]
- Nakamae, T.; Shinozuka, T.; Sasaki, C.; Ogamo, A.; Murakami-Hashimoto, C.; Irie, W.; Terada, M.; Nakamura, S.; Furukawa, M.; Kurihara, K. Case report: Etizolam and its major metabolites in two unnatural death cases. Forensic Sci. Int. 2008, 182, e1–e6. [Google Scholar] [CrossRef]
- Tanaka, N.; Kinoshita, H.; Nishiguchi, M.; Jamal, M.; Kumihashi, M.; Takahashi, M.; Nishio, H.; Ameno, K. An autopsy case of multiple psychotropic drug poisoning. Soud. Lek. 2011, 56, 38–39. [Google Scholar]
- Liveri, K.; Constantinou, M.A.; Afxentiou, M.; Kanari, P. A fatal intoxication related to MDPV and pentedrone combined with antipsychotic and antidepressant substances in Cyprus. Forensic Sci. Int. 2016, 265, 160–165. [Google Scholar] [CrossRef]
- Hikin, L.J.; Smith, P.R.; Maskell, P.D.; Kurimbokus, H.; Ashong, E.; Couchman, L.; Morley, S.R. Femoral blood concentrations of the designer benzodiazepine etizolam in post-mortem cases. Med. Sci. Law 2021, 61, 122–129. [Google Scholar] [CrossRef]
- Kolbe, V.; Rentsch, D.; Boy, D.; Schmidt, B.; Kegler, R.; Büttner, A. The adulterated XANAX pill: A fatal intoxication with etizolam and caffeine. Int. J. Legal Med. 2020, 134, 1727–1731. [Google Scholar] [CrossRef]
- Gevorkyan, J.; Kinyua, J.; Pearring, S.; Rodda, L.N. A Case Series of Etizolam in Opioid Related Deaths. J. Anal. Toxicol. 2020, bkaa146. [Google Scholar] [CrossRef]
- Blumenberg, A.; Hughes, A.; Reckers, A.; Ellison, R.; Gerona, R. Flualprazolam: Report of an outbreak of a new psychoactive substance in adolescents. Pediatrics 2020, 146, e20192953. [Google Scholar] [CrossRef] [PubMed]
- Wagmann, L.; Manier, S.K.; Bambauer, T.P.; Felske, C.; Eckstein, N.; Flockerzi, V.; Meyer, M.R. Toxicokinetics and analytical toxicology of flualprazolam: Metabolic fate, isozyme mapping, human plasma concentration and main urinary excretion products. J. Anal. Toxicol. 2020, 44, 549–558. [Google Scholar] [CrossRef] [PubMed]
- Krotulski, A.J.; Papsun, D.M.; Noble, C.; Kacinko, S.L.; Logan, B.K. Brorphine-Investigation and quantitation of a new potent synthetic opioid in forensic toxicology casework using liquid chromatography-mass spectrometry. J. Forensic Sci. 2021, 66, 664–676. [Google Scholar] [CrossRef] [PubMed]
- Papsun, D.M.; Krotulski, A.J.; Homan, J.; Temporal, K.D.H.; Logan, B.K. Flualprazolam Blood Concentrations in 197 Forensic Investigation Cases. J. Anal. Toxicol. 2021, 45, 226–232. [Google Scholar] [CrossRef]
- Kriikku, P.; Rasanen, I.; Ojanperä, I.; Thelander, G.; Kronstrand, R.; Vikingsson, S. Femoral blood concentrations of flualprazolam in 33 postmortem cases. Forensic Sci. Int. 2020, 307, 110101. [Google Scholar] [CrossRef]
- Rice, K.; Hikin, L.; Lawson, A.; Smith, P.R.; Morley, S. Quantification of Flualprazolam in Blood by LC-MS-MS: A Case Series of Nine Deaths. J. Anal. Toxicol. 2021, 45, 410–416. [Google Scholar] [CrossRef]
- Valli, A.; Lonati, D.; Locatelli, C.A.; Buscaglia, E.; Di Tuccio, M.; Papa, P. Analytically diagnosed intoxication by 2-methoxphenidine and flubromazepam mimicking an ischemic cerebral disease. Clin. Toxicol. 2017, 55, 611–612. [Google Scholar] [CrossRef]
- Koch, K.; Auwärter, V.; Hermanns-Clausen, M.; Wilde, M.; Neukamm, M.A. Mixed intoxication by the synthetic opioid U-47700 and the benzodiazepine flubromazepam with lethal outcome: Pharmacokinetic data. Drug Test. Anal. 2018, 10, 1336–1341. [Google Scholar] [CrossRef]
- Łukasik-Głębocka, M.; Sommerfeld, K.; Tezyk, A.; Zielińska-Psuja, B.; Panieński, P.; Zaba, C. Flubromazolam—A new life-threatening designer benzodiazepine. Clin. Toxicol. 2016, 54, 66–68. [Google Scholar] [CrossRef]
- Ellefsen, K.N.; Taylor, E.A.; Simmons, P.; Willoughby, V.; Hall, B.J. Multiple drug-toxicity involving novel psychoactive substances, 3-Fluorophenmetrazine and U-47700. J. Anal. Toxicol. 2017, 41, 765–770. [Google Scholar] [CrossRef]
- Abdul, K.; Hikin, L.; Smith, P.; Kurimbokus, H.; Ashong, E.; Couchman, L.; Morley, S.R. Flubromazolam: Detection in five post-mortem cases. Med. Sci. Law 2020, 60, 266–269. [Google Scholar] [CrossRef]
- Huppertz, L.M.; Moosmann, B.; Auwärter, V. Flubromazolam—Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Test. Anal. 2018, 10, 206–211. [Google Scholar] [CrossRef]
- Mrozkowska, J.; Borna, C.; Vinge, E. Missbruk av fenazepam—Ny färeteelse i Sverige. Bensodiazepinderivat från Ryssland gav svår intoxikation. Lakartidningen 2009, 106, 516–517. [Google Scholar] [PubMed]
- Dargan, P.I.; Davies, S.; Puchnarewicz, M.; Johnston, A.; Wood, D.M. First reported case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically confirmed recreational use of phenazepam. Eur. J. Clin. Pharmacol. 2013, 69, 361–363. [Google Scholar] [CrossRef] [PubMed]
- Vo, K.T.; van Wijk, X.M.R.; Wu, A.H.B.; Lynch, K.L.; Ho, R.Y. Synthetic agents off the darknet: A case of U-47700 and phenazepam abuse. Clin. Toxicol. 2017, 55, 71–72. [Google Scholar] [CrossRef]
- Kriikku, P.; Wilhelm, L.; Rintatalo, J.; Hurme, J.; Kramer, J.; Ojanperä, I. Phenazepam abuse in Finland: Findings from apprehended drivers, post-mortem cases and police confiscations. Forensic Sci. Int. 2012, 220, 111–117. [Google Scholar] [CrossRef] [PubMed]
- Stephenson, J.B.; Golz, D.E.; Brasher, M.J. Phenazepam and its effects on driving. J. Anal. Toxicol. 2013, 37, 25–29. [Google Scholar] [CrossRef] [Green Version]
- Kerrigan, S.; Mellon, M.B.; Hinners, P. Detection of phenazepam in impaired driving. J. Anal. Toxicol. 2013, 37, 605–610. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bailey, K.; Richards-Waugh, L.; Clay, D.; Gebhardt, M.; Mahmoud, H.; Kraner, J.C. Fatality involving the ingestion of phenazepam and poppy seed tea. J. Anal. Toxicol. 2010, 34, 527–532. [Google Scholar] [CrossRef] [Green Version]
- Corkery, J.M.; Schifano, F.; Ghodse, A.H. Phenazepam abuse in the UK: An emerging problem causing serious adverse health problems, including death. Hum. Psychopharmacol. 2012, 27, 254–261. [Google Scholar] [CrossRef]
- Crichton, M.L.; Shenton, C.F.; Drummond, G.; Beer, L.J.; Seetohul, L.N.; Maskell, P.D. Analysis of phenazepam and 3-hydroxyphenazepam in post-mortem fluids and tissues. Drug Test. Anal. 2015, 7, 926–936. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shearer, K.; Bryce, C.; Parsons, M.; Torrance, H. Phenazepam: A review of medico-legal deaths in South Scotland between 2010 and 2014. Forensic Sci. Int. 2015, 254, 197–204. [Google Scholar] [CrossRef] [Green Version]
- Lehmann, S.; Sczyslo, A.; Froch-Cortis, J.; Rothschild, M.A.; Thevis, M.; Andresen-Streichert, H.; Mercer-Chalmers-Bender, K. Organ distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine. Forensic Sci. Int. 2019, 303, 109959. [Google Scholar] [CrossRef]
- Venkatakrishnan, K.; Culm, K.E.; Ehrenberg, B.L.; Harmatz, J.S.; Corbett, K.E.; Fleishaker, J.C.; Greenblatt, D.J. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. J. Clin. Pharmacol. 2005, 45, 529–537. [Google Scholar] [CrossRef] [PubMed]
- Cornett, E.M.; Novitch, M.B.; Brunk, A.J.; Davidson, K.S.; Menard, B.L.; Urman, R.D.; Kaye, A.D. New benzodiazepines for sedation. Best Pract. Res. Clin. Anaesthesiol. 2018, 32, 149–164. [Google Scholar] [CrossRef]
- Hicks, F.; Robins, E.; Murphy, G.E. Comparison of adinazolam, amitriptyline, and placebo in the treatment of melancholic depression. Psychiatry Res. 1988, 23, 221–227. [Google Scholar] [CrossRef]
- Fleishaker, J.C.; Phillips, J.P.; Smith, T.C.; Smith, R.B. Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects. Pharm. Res. 1989, 6, 379–386. [Google Scholar] [CrossRef] [PubMed]
- Fleishaker, J.C.; Phillips, J.P. Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers. Psychopharmacology 1989, 99, 34–39. [Google Scholar] [CrossRef]
- EMCDDA. New benzodiazepines in Europe—A review. Available online: https://www.emcdda.europa.eu/system/files/publications/13759/TD0221596ENN_002.pdf (accessed on 10 June 2021).
- Moosmann, B.; Bisel, P.; Franz, F.; Huppertz, L.M.; Auwärter, V. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines—An update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam. J. Mass Spectrom. 2016, 51, 1080–1089. [Google Scholar] [CrossRef]
- CFSRE. Adinazolam Monograph. Available online: https://www.npsdiscovery.org/wp-content/uploads/2020/08/Adinazolam_081120_CFSRE-Toxicology_Report.pdf (accessed on 20 March 2021).
- Maskell, P.D.; Parks, C.; Button, J.; Liu, H.; McKeown, D.A. Clarification of the Correct Nomenclature of the Amino Metabolite of Clonazolam: 8-Aminoclonazolam. J. Anal. Toxicol. 2021, 45, e1–e2. [Google Scholar] [CrossRef]
- Grossenbacher, F.; Souille, J.; Djerrada, Z.; Passouant, O.; Gibaja, V. Exposure to 5f-P22, 5 IAI and diclazepam: A case report. Clin. Toxicol. 2014, 52, 365. [Google Scholar]
- Nielsen, S.; McAuley, A. Etizolam: A rapid review on pharmacology, non-medical use and harms. Drug Alcohol Rev. 2020, 39, 330–336. [Google Scholar] [CrossRef] [PubMed]
- Busardò, F.P.; Di Trana, A.; Montanari, E.; Mauloni, S.; Tagliabracci, A.; Giorgetti, R. Is etizolam a safe medication? Effects on psychomotor perfomance at therapeutic dosages of a newly abused psychoactive substance. Forensic Sci. Int. 2019, 301, 137–141. [Google Scholar] [CrossRef]
- EMCDDA. Europol 2011 Annual Report on the Implementation of Council Decision 2005/387/JHA. Available online: https://www.emcdda.europa.eu/system/files/publications/689/EMCDDA-Europol_Annual_Report_2011_2012_final_335568.pdf (accessed on 14 February 2021).
- Lim, W.J.L.; Yap, A.T.W.; Mangudi, M.; Koh, H.B.; Tang, A.S.Y.; Chan, K.B. Detection of phenazepam in illicitly manufactured Erimin 5 tablets. Drug Test. Anal. 2017, 9, 293–305. [Google Scholar] [CrossRef]
- Couch, R.A.F.; Madhavaram, H. Phenazepam and cannabinomimetics sold as herbal highs in New Zealand. Drug Test. Anal. 2012, 4, 409–414. [Google Scholar] [CrossRef]
- EMCDDA. Europol 2012 Annual Report on the Implementation of Council Decision 2005/387/JHA. Available online: https://www.emcdda.europa.eu/system/files/publications/734/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf (accessed on 4 April 2021).
- EMCDDA. New Psychoactive Substances: Global Markets, Glocal Threats and the COVID-19 Pandemic—An Update from the EU Early Warning System. Available online: https://www.emcdda.europa.eu/system/files/publications/13464/20205648_TD0320796ENN_PDF_rev.pdf (accessed on 4 April 2021).
- EMCDDA. European Drug Report 2016: Trends and Developments. Available online: https://www.emcdda.europa.eu/system/files/publications/2637/TDAT16001ENN.pdf (accessed on 4 April 2021).
- EMCDDA. European Drug Report 2019: Trends and Developments. Available online: https://www.emcdda.europa.eu/system/files/publications/11364/20191724_TDAT19001ENN_PDF.pdf (accessed on 4 April 2021).
- EMCDDA. European Drug Report 2018: Trends and Developments. Available online: http://www.emcdda.europa.eu/publications/edr/trends-developments/2018 (accessed on 4 April 2021).
- National Records of Scotland. Drug-Related Deaths in Scotland Rose in 2019. Available online: https://www.nrscotland.gov.uk/files//statistics/drug-related-deaths/2019/drug-related-deaths-19-pub.pdf (accessed on 3 May 2021).
- NFLIS. Drug Snapshot (December 2020). Available online: https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLIS_Snapshot_122020.pdf (accessed on 4 April 2021).
- CFSRE. NPS Benzodiazepines in the United States—Trend Report: Q1 2021. Available online: https://www.npsdiscovery.org/wp-content/uploads/2021/04/2021-Q1_NPS-Benzodiazepines_Trend-Report.pdf (accessed on 4 April 2021).
- Direction De Santé Publique De La Montérégie. Agrégat De Surdoses Liées À La Consommation De Contrefaçons D ‘ Alprazolam (Xanax) Dans Un Milieu Scolaire. Available online: http://extranet.santemonteregie.qc.ca/userfiles/file/sante-publique/maladies-infectieuses/Appel-vigilance-Surdose-contexte-scolaire.pdf (accessed on 25 April 2021).
- EMCDDA. EU Drug Markets Report 2019. Available online: https://www.emcdda.europa.eu/system/files/publications/12078/20192630_TD0319332ENN_PDF.pdf (accessed on 25 April 2021).
- UNODC. Global SMART Programme. Synthetic Drugs in East and South-East Asia 2019: Trends and Patterns of Amphetamine-type Stimulants and New Psychoactive Substances. Available online: https://www.unodc.org/documents/southeastasiaandpacific/Publications/2019/2019_The_Challenge_of_Synthetic_Drugs_in_East_and_SEA.pdf (accessed on 25 April 2021).
- UNODC. Darknet Cybercrime Threats to Southeast Asia. 2020. Available online: https://www.unodc.org/documents/southeastasiaandpacific//Publications/2021/Darknet_Cybercrime_Threats_to_Southeast_Asia_report.pdf (accessed on 25 April 2021).
- Abouchedid, R.; Gilks, T.; Dargan, P.I.; Archer, J.R.H.; Wood, D.M. Assessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances—Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam—In the UK. J. Med. Toxicol. 2018, 14, 134–143. [Google Scholar] [CrossRef] [PubMed]
- EMCDDA. European Drug Report 2014: Trends and Developments. Available online: https://www.emcdda.europa.eu/publications/edr/trends-developments/2014_en (accessed on 25 April 2021).
- UNODC. Global SMART Update Volume 25. Regional Diversity and the Impact of Scheduling on NPS Trends. Available online: https://www.unodc.org/documents/scientific/Global_SMART_Update_2021-Vol.25-Eng-Final.pdf (accessed on 25 April 2021).
- ACMD. Novel Benzodiazepines: A Review of the Evidence of Use and Harms of Novel Benzodiazepines. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/881969/ACMD_report_-_a_review_of_the_evidence_of_use_and_harms_of_novel_benzodiazepines.pdf (accessed on 25 April 2021).
- Andersson, M.; Kjellgren, A. The slippery slope of flubromazolam: Experiences of a novel psychoactive benzodiazepine as discussed on a Swedish online forum. NAD Nord. Stud. Alcohol Drugs 2017, 34, 217–229. [Google Scholar] [CrossRef]
- Ameline, A.; Richeval, C.; Gaulier, J.M.; Raul, J.S.; Kintz, P. Characterization of flunitrazolam, a new designer benzodiazepine, in oral fluid after a controlled single administration. J. Anal. Toxicol. 2018, 42, e58–e60. [Google Scholar] [CrossRef]
- Carpenter, J.E.; Murray, B.P.; Dunkley, C.; Kazzi, Z.N.; Gittinger, M.H. Designer benzodiazepines: A report of exposures recorded in the National Poison Data System, 2014–2017. Clin. Toxicol. 2019, 57, 282–286. [Google Scholar] [CrossRef] [PubMed]
- Kyle, P.B.; Brown, K.B.; Bailey, A.P.; Stevenson, J.L. Reactivity of commercial benzodiazepine immunoassays to phenazepam. J. Anal. Toxicol. 2012, 36, 207–209. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Moosmann, B.; Bisel, P.; Westphal, F.; Wilde, M.; Kempf, J.; Angerer, V.; Auwärter, V. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4′-chlorodiazepam (Ro5–4864). Drug Test. Anal. 2019, 11, 541–549. [Google Scholar] [CrossRef] [PubMed]
- Moosmann, B.; Auwärter, V. Designer benzodiazepines: Another class of new psychoactive substances. Handb. Exp. Pharmacol. 2018, 252, 383–410. [Google Scholar] [CrossRef]
- McAuley, A.; Hecht, G.; Barnsdale, L.; Thomson, C.S.; Graham, L.; Priyadarshi, S.; Robertson, J.R. Mortality related to novel psychoactive substances in Scotland, 2012: An exploratory study. Int. J. Drug Policy 2015, 26, 461–467. [Google Scholar] [CrossRef]
- Giaginis, C.; Tsantili-Kakoulidou, A.; Theocharis, S. Applying quantitative structure-activity relationship (QSAR) methodology for modeling postmortem redistribution of benzodiazepines and tricyclic antidepressants. J. Anal. Toxicol. 2014, 38, 242–248. [Google Scholar] [CrossRef] [Green Version]
Compound | Study | Age; Sex | Observations | Concentration †/Dose | Co-Exposure Concentration(s) † | Ref. |
---|---|---|---|---|---|---|
3-Hydroxyphenazepam | ED | 29; M | Tremor | Urine screen + | - | [74] |
Adinazolam | Death | 24; F | Multiple drugs | Blood 18 Urine 82.1 | U-47700 blood 1470, urine 3940 SRT blood 89.5, urine 32.5 N-Ethylhexedrone blood 58.1, urine 14 4-CIC blood 8, urine 130 4-CMC blood 1.7, urine 417 | [75] |
Clonazolam | ED | 25; M | Agitation, Aggressivity | 100 mg | BZD urine screen + THC urine screen + | [76] |
28; M | Lethargy | ≅15 mL of a 0.4 mg/mL solution | - | [77] | ||
26; M | Respiratory depression, Unconscious | Serum 6 | MDZ urine screen + U-47700 serum 351 THC serum 3.3, urine screen + THCCOOH serum 121.6, urine screen + CIT urine screen + | [78] | ||
34; M | Confusion, Lethargy | Serum 10.2 | Etizolam serum 281 | [79] | ||
20; M | Ataxia | Urine screen + | MXE urine screen + | [74] | ||
26; F | Coma | Blood 77 (4 h) Blood 15 (8 h) Blood 9 (12 h) | - | [80] | ||
Deschloroetizolam | Death | 31; M | Multi-organ congestion | Blood 11 Urine screen + | LMZ urine 258 LZP urine 115 OXZ urine 17.4 THC urine screen + | [81] |
Self-administration | 56; M | Dizziness, Fatigue, Language disorder, Difficulty concentrating; Took 6 mg | Oral Fluid 6.5 (30 min) | - | [82] | |
Diclazepam | ED | 30; M | Agitation, Confusion, Disorientation, Inability to communicate, Muscular rigidity, Myosis, Tachycardia, Tachypnoea | Plasma 3.5 | DIP plasma 308, urine 631 MPH plasma 3 THCCOOH urine 120 | [83] |
39; M | Agitation, Dilated pupils, Tachycardia | Urine screen + | 3,4-CTMP | [74] | ||
30; M | Mydriasis, Respiratory depression, Unconscious, Withdrawal syndrome. | 240 mg | - | [84] | ||
DUID | 18; M | Considerable impairment | Blood 57 | - | [85] | |
27 *; Not reported | Moderate impairment | Blood 61 | EtOH blood 0.053 g/L | [86] | ||
32 *; Not reported | Blood 45 | EtOH blood 0.084 g/L | ||||
22 *; Not reported | Blood 32 | - | ||||
<20; Not reported | Blood 19 | - | ||||
47 *; Not reported | Blood 16 | LZP blood 63 | ||||
52 *; Not reported | Blood 11 | NZP blood 17 | ||||
22 *; Not reported | Mild impairment | Blood 35 | LZP blood 14 | |||
22 *; Not reported | Blood 7.7 | THC blood 0.7 | ||||
22 *; Not reported | Blood 5.1 | - | ||||
37 *; Not reported | Considerable impairment | Blood 48 | - | |||
27 *; Not reported | Blood 35 | THC blood 1.1 | ||||
32 *; Not reported | Blood 14 | - | ||||
Death | 28; M | Multiple drugs | Blood 70 | Flubromazepam blood 10 U-47700 blood 330 MAMP blood 290 AMP blood 150 DOC blood screen + | [87] | |
Etizolam | ED | 31; M | Bradypnea, Unresponsive | Serum 103 | 6-AM urine 272 MOR urine 1000 COD urine 322 | [88] |
6; M | Ataxia, Drowsiness, Mydriasis | - | - | [89] | ||
9; M | - | - | ||||
10; M | Urine screen + | - | ||||
OD | 23; M | Tolerance, Withdrawal syndrome | 2.5 mg/day for 1 month | - | [90] | |
32; M | Catatonia, Withdrawal syndrome | 4 mg/day for 2 months, abruptly stopped | - | [91] | ||
30; M | Bradypnea, Loss of consciousness, Seizures, Withdrawal syndrome | Took 50 mg/day to 100 mg/day for several months Urine screen + | LZP urine screen + | [45] | ||
DUID | 27 *; Not reported | Mild impairment | Blood 210 | - | [86] | |
<20; Not reported | Blood 120 | TMD blood 71 | ||||
42 *; Not reported | Considerable impairment | Blood 110 | - | |||
37; M | Delayed comprehension and reaction time, Impairment, Incoordination, Lethargy | Blood 40 | AMP blood screen + | [71] | ||
20; F | Blood 88 | THC blood 11 | ||||
35; M | Blood 330 | MAMP blood screen + AMP blood screen + | ||||
Death | 59; F | Suicide | Blood 264 | αOH-Etizolam blood 9.4 8OH-Etizolam blood 9.3 | [92] | |
42; M | Multiple drugs | Blood 86 | PB blood 5082, urine 1736 PMZ blood 107, urine 806 CPZ blood 144, urine 1437 | [93] | ||
42; M | Multiple drugs | Blood 300 Urine 100 | MDVP blood 46, urine 1300 PEN blood 160, urine 1200 EPH blood 68 OLZ blood 4200 MIR blood 570 | [94] | ||
48; M | Accidental death, Multiple drugs | Serum 4 | MTD serum 381 EDDP serum 86 MOR serum 290 COD serum 47 PGB serum 14 PAR serum screen + | [95] | ||
40; M | Serum 17 | MOR serum 44 COD serum 7 COC serum screen + BE serum 1536 | ||||
29; M | Serum 40 | DZP serum screen + Nor-DZP serum 18 OXZ serum screen + MTD serum 133 EDDP serum 7 THC serum 2.4 THCCOOH serum 17 PGB serum 19 CYC serum 78 | ||||
38; M | Serum 44 | DZP serum 55 Nor-DZP serum 131 OXZ serum 11 MTD serum 886 EDDP serum 121 SRT serum 6 PMZ serum 57 PGB serum 13000 | ||||
48; M | Blood 4 | DZP blood 99 Nor-DZP blood 316 TMZ blood 15 OXZ blood 29 MOR blood 6 COD blood 83 AMP blood 394 AMI blood 307 NTP blood 283 PAR blood screen + | ||||
34; M | Blood 8 | Diclazepam blood 2 COD blood 108 CIT blood 423 Nor-CIT blood 93 | ||||
23; M | Blood 8 | EtOH blood 0.77 g/L ALP blood 300 Nor-DZP blood 5 MOR blood 5 COD blood 16 BE blood screen + SRT blood 19 PPL blood 8 | ||||
55; M | Blood 7 | DHC blood 1681 COC blood 317 BE blood 5135 AMI blood 1859 NTP blood 582 PGB blood 22300 | ||||
39; M | Blood 45 | MTD blood 377 COC blood 18 AMI blood 885 PGB blood 6500000 | ||||
38; M | Blood 172 | DZP blood 6 Nor-DZP blood 22 LZP blood screen + MTD blood 1233 EDDP blood 129 MOR blood 16 COD blood screen + COC blood 10 BE blood 299 THCCOOH blood 11.2 MIR blood 27 PGB blood 35900 | ||||
32; F | Blood 9 | DZP blood 306 MTD blood 86 MOR blood 1292 COC blood 7 MIR blood 6 PAR blood 22000 | ||||
43; M | Blood 93 | DZP blood screen + ZPC blood 65 MTD blood 2297 COC blood screen + MIR blood 8 PGB blood 3700 | ||||
42; M | Blood 85 | DZP blood 16 MOR blood 880 | ||||
37; M | Blood 85 | MTD blood 189 PGB blood 8500 | ||||
32; M | Blood 4 | DZP blood 107 MOR blood 273 AMP blood 859 CPA blood screen + GBP blood 2600 PGB blood 10300 PAR blood screen + | ||||
35; M | Blood 16 | MOR blood 269 COC blood screen + SRT blood 24 CBZ blood 2300 PGB blood 23,500 | ||||
39; F | Blood 1 | DZP blood 431 MTD v blood 634 PMZ blood 56 MIR blood 61 QTP blood 26 VPA blood screen + PGB blood 22,800 PAR blood screen + | ||||
32; M | Blood 18 | DZP blood 131 MOR blood 34 DHC blood 6413 HCOD blood 96 AMI blood 310 PGB blood 10,200 | ||||
49; M | Blood 1.5 | Flubromazepam blood 33 DZP blood 89 MTD blood 685 MOR blood 44 MIR blood 12 PGB blood 38,100 | ||||
54; F | Blood 12 | DZP blood 90 MTD blood 973 TMD blood screen + COC blood 12 AMI blood 67 MIR blood 280 PGB blood 12,900 | ||||
39; M | Blood 4 | EtOH blood 0.24 g/L DZP blood 68 MOR blood 1076 COC blood 184 CE blood 22 MIR blood 121 QTP blood 16 PAR blood screen + | ||||
49; M | Blood 12 | CZP blood screen + TAP blood 500 MOR blood 331 PGB blood 15,200 MIR blood screen + | ||||
28; M | Blood 29 | EtOH blood 1.1 g/L DZP blood 16 THC blood 57.5 MIR blood 39 PGB blood 2900 | ||||
39; M | Blood 3 | DZP blood 238 LZP blood 10 MOR blood 75 SRT blood 92 GBP blood 6700 PRO blood 598 PAR blood 15,700 | ||||
33; M | Blood 14 | Flubromazolam blood 1 DZP blood screen + MOR blood 56 COC v blood 46 PRO blood 186 CLO blood 2060 Nor-CLO blood 1629 MIR blood 257 LTG blood 5800 GBP blood 24,600 PAR blood screen + | ||||
49; M | Accidental death, Multiple drugs | Blood 770 Central blood 2820 Hair 0.107 | EtOH blood 0.19 g/L THCCOOH urine 192 THC hair 0.19 ng/mg AMP hair 3.37 ng/mg CAF blood 190,000 COC hair 0.22 ng/mg BE hair 0.068 ng/mg | [96] | ||
29; M | Accidental death, Multiple drugs | Central blood 45 Urine 13 Vitreous humor screen + | EtOH c blood 0.023 g/L, vitreous humor 0.014 g/L ALP c blood 228, urine 238, vitreous humor 17 α-OH-ALP c blood and urine screen + Nor-DZP c blood, urine and vitreous humor screen + FEN c blood 6, urine and vitreous humor screen + Nor-FEN c blood and urine screen + CDP c blood screen + DOX urine and vitreous humor screen + | [97] | ||
34; M | Blood 9 Central blood screen + Urine screen + Vitreous humor screen + | EtOH blood 0.023 g/L, vitreous humor 0.028 g/L Nor-DZP blood and urine screen + Desalkyl-FZP blood, urine and vitreous humor screen + 6-AM blood 11, c blood, urine and vitreous humor screen + MOR blood 185, c blood, urine and vitreous humor screen + COD p and c blood and vitreous humor screen + HCOD c blood and vitreous humor screen + CIT p and c blood, urine and vitreous humor screen + DPH p and c blood, urine and vitreous humor screen + | ||||
36; M | Blood 10 Urine 8 Vitreous humor screen + | Flubromazolam urine and vitreous humor screen + ALP blood 27, urine and vitreous humor screen + α-OH-ALP urine and vitreous humor screen + 7-Amino-CZP urine screen + FEN blood 31, vitreous humor screen + Nor-FEN blood and vitreous humor screen + MTD blood and vitreous humor screen + EDDP blood and vitreous humor screen + MAMP blood 1212, vitreous humor screen + AMP blood and vitreous humor screen + | ||||
28; M | Blood 15 Central blood 15 Urine 20 | ALP blood 179, c blood 235, urine screen +, vitreous humor 92 DZP p and c blood, urine and vitreous humor screen + Nor-DZP p and c blood, urine and vitreous humor screen + TMZ c blood and urine screen + Nor-FEN c blood and vitreous humor screen + HCOD urine screen + MAMP p and c blood, urine and vitreous humor screen + AMP c blood, urine and vitreous humor screen + BE urine screen + DOX p and c blood, urine and vitreous humor screen + PMZ c blood and urine screen + CPA p and c blood, urine and vitreous humor screen + | ||||
30; M | Blood 187 Central blood 214 Urine 64 Vitreous humor 33 | EtOH blood 0.002 g/L, vitreous humor 0.003 g/L Flualprazolam p and c blood, urine and vitreous humor screen + Flubromazolam blood 619, c blood 878, urine 552, vitreous humor screen + ALP p and c blood, urine and vitreous humor screen + DLP p and c blood, urine and vitreous humor screen + LZP p and c blood and urine screen + 7-Amino-CZP urine screen + FEN blood 17 Nor-FEN p and c blood, urine and vitreous humor screen + MAMP p and c blood, urine and vitreous humor screen + AMP p and c blood, urine and vitreous humor screen + | ||||
Flualprazolam | ED | 16; M | Lethargy, Slurred speech | Urine 72.1 | Nor-DZP urine screen + THC-COOH urine screen + | [98] |
16; F | Urine 3 | Nor-DZP urine screen + | ||||
16; M | CNS depression, Mild respiratory depression | Blood 14.6 Urine 19.4 | Nor-DZP urine screen + | |||
18; M | Unconscious | Blood 8 | COC blood screen + THC blood screen + | [99] | ||
DUID | 37 *; Not reported | Considerable impairment | Blood 15 | TMD blood 65 | [86] | |
Not reported | Considerable impairment | Blood 4.3 | DZP blood 25 BRP blood 1 FEN blood 6.2 COC blood 57 | [100] | ||
31; M | Delayed comprehension and reaction time, Driving impairment, Incoordination, Lethargy | Blood 4.4 | THC-COOH blood screen + LEV blood screen + | [101] | ||
22; M | Blood 8.3 | EtOH blood 0.01 g/L | ||||
31; M | Blood 8.9 | Etizolam blood screen + ALP blood screen + DLP blood screen + Nor-BUP blood screen + THC blood screen + | ||||
51; M | Blood 10 | OXY blood screen + OXM blood screen + | ||||
47; M | Blood 11 | CFN blood screen + FEN blood screen + MTD blood screen + COC blood screen + | ||||
24; M | Blood 13 | - | ||||
30; M | Blood 39 | BE blood screen + MTG blood screen + | ||||
20; M | Blood 46 | EtOH blood 0.003 g/L | ||||
40; M | Blood 46 | BPP blood screen + | ||||
20; M | Blood 65 | THC blood screen + | ||||
26; M | Blood 68 | Etizolam blood screen + MTD blood screen + | ||||
Death | 28 *; Not reported | Suicide | Blood 28 ng/g | MIR blood 200 ng/g VEN blood 520 ng/g | [102] | |
Blood 68 ng/g | EtOH blood 0.04 g/L BUP blood 0.94 ng/g, urine 17 ng/g Nor-BUP blood 0.83 ng/g, urine 15 ng/g | |||||
Suspected overdose, Multiple drugs | Blood 4 ng/g | VEN blood 1300 ng/g PGB blood 16000 ng/g | ||||
Blood 18 ng/g | MTD blood 150 ng/g | |||||
Blood 17 ng/g | EtOH blood 0.67 g/L, urine 1.33 g/L BUP blood 2.8 ng/g, urine 90 | |||||
Blood 19 ng/g | - | |||||
Blood 14 ng/g | LPM blood 60 ng/g | |||||
Blood 21 ng/g | - | |||||
Blood 11 ng/g | BUP blood 0.9 ng/g, urine 40 NBUP blood 0.2 ng/g | |||||
Blood 36 ng/g | BUP urine 120 ng/g NBUP urine 7.4 ng/g PGB blood 1700 ng/g | |||||
Blood 30 ng/g | EtOH blood 0.68 g/L BUP blood 1.1 ng/g, urine200 ng/g 3F-AMP blood 10 ng/g MAMP blood 190 ng/g AMP blood 1000 ng/g | |||||
Blood 13 ng/g | EtOH blood 1.9 g/L | |||||
Blood 33 ng/g | N-ethyl-3F-AMP blood screen + 3F-AMP blood screen + | |||||
53; M | Suspected overdose, Multiple drugs | Blood 50 | FEN blood 3.4 Nor-FEN blood 0.36 4-ANPP blood screen + ITZ blood screen + BRP blood 10, urine 23 6-AM blood 1.5 MOR blood 66 COD blood 6.6 CIT/ESC blood 76 | [100] | ||
45; M | Blood 2.5 | FEN blood 5 4-ANPP blood screen + TMD blood 33 BRP blood 1, urine 1.9 THC blood 0.62 | ||||
48; M | Blood 5.4 | CZP blood screen + FEN blood 4.7 Nor-FEN blood 1.6 Acetyl-FEN blood 1.2 4-ANPP blood screen + BRP blood 0.1, urine 0.2 MOR blood 8 DPH blood 190 | ||||
47; F | Blood 13 | FEN blood 190 Nor-FEN blood 5.4 Acetyl-FEN 0.15 4-ANPP blood screen + BRP blood 6.7, urine 2.1 6-AM blood 12 MOR blood 85 COD blood 7 MAMP blood 580 AMP blood 55 XYL blood 170 | ||||
53; M | Blood 20 | FEN blood 19 Nor-FEN blood 4.2 4-ANPP blood screen + BRP blood 0.2 MOR blood 15 XYL blood 30 | ||||
29; M | Blood 3.6 | 7-Amino-CZP blood 5.2 FEN blood 37 Nor-FEN blood 1.3 4-ANPP blood screen + TMD blood 70 BRP blood 1.1, urine 0.8 MAMP blood 42 AMP blood 10 DPH blood 490 | ||||
22; M | Suspected overdose, Multiple drugs | Blood 3.2 | EtOH blood 0.017 Desmethyl-LPM blood screen + | [101] | ||
53; M | Blood 2.1 | FEN blood screen + MTD blood screen + COC blood screen + GBP blood screen + | ||||
32; M | Blood 2.2 | BE blood screen + THC blood screen + MTG blood screen + CBP blood screen + HYZ blood screen + GBP blood screen + | ||||
29; M | Blood 4.1 | ITZ blood screen + MAMP blood screen + AMP blood screen + | ||||
35; F | Blood 5.2 | EtOH blood 0.008 g/L BE blood screen + THC blood screen + | ||||
38; M | Blood 6.2 | ITZ blood screen + FEN blood screen + MAMP blood screen + AMP blood screen + HYZ blood screen + | ||||
23; F | Blood 9.9 | FEN blood screen + 4-ANPP blood screen + BE blood screen + THC blood screen + MAMP blood screen + AMP blood screen + | ||||
23; M | Blood 15 | FEN blood screen + 4-ANPP blood screen + | ||||
21; M | Blood 29 | FEN blood screen + MAMP blood screen + AMP blood screen + THC blood screen + | ||||
36; M | Blood 63 | MTD blood screen + | ||||
40; M | Suicide | Blood 26.5 | DZP blood 9 Nor-DZP blood 4 MTD blood 736 EDDP blood 149 PGB blood 1900 | [103] | ||
30; M | Suspected overdose, Multiple drugs | Blood 3 | DZP blood screen + 6-AM blood screen + MOR blood 196 COD blood 11 THC blood screen + MIR blood screen + PGB blood 12000 | |||
44; M | Blood 35 | DZP blood screen + MTD blood 549 MOR blood screen + COC blood screen + BE blood screen + MDMA blood 29 MDA blood screen + MIR blood 58 GBP blood screen + PGB blood 18,100 | ||||
40; F | Blood 14.5 | MTD blood 711 EDDP blood 67 4F-MDMB-BINACA blood screen + MDMB-4en-PINACA blood screen + MIR blood 3229 PGB blood 7900 | ||||
37; M | Blood 14.1 | Etizolam blood 85 CBZ metabolites blood screen + MTD blood 189 5F-AMB metabolites blood screen + THC metabolites blood screen + PGB blood 8500 | ||||
51; M | Blood 3.1 | ALP blood 68 DZP blood 367 Nor-DZP blood 364 OXZ blood 45 TMZ blood 19 MTD blood 694 EDDP blood 365 MOR blood 62 COD blood 14 BE blood screen + SRT blood 31 PGB blood 47,000 RSP blood 35 | ||||
57; M | Blood 5.7 | COC blood 41 BE blood 718 CIT blood 707 | ||||
42; F | Blood 15.1 | MOR blood 410 COD blood 19 PGB blood 9900 | ||||
42; M | Blood 9 | ALP blood 35 CZP blood 7 DZP blood 61 Nor-DZP blood 82 NZP blood 16 BUP blood 0.5 MOR blood 197 COD blood 11 COC blood screen + BE blood 258 MIR blood 23 PGB blood 900 | ||||
Flubromazepam | ED | 25; M | Agitation, Aphasia, Ataxia, Confusion, Dysarthria, Hypertension, Hyposthenia | Blood 411 | BZD urine screen + THC urine screen + MXP blood 247 | [104] |
24; M | Agitation, Coma, Delirium, Mydriasis, Rigidity, Tachycardia, Tremor | Urine screen + | - | [74] | ||
47; M | Urine screen + | 3OH-Flubromazepam urine screen + | ||||
45; M | Urine screen + | 3OH-Flubromazepam urine screen + | ||||
DUID | 37; M | Mild impairment | Blood 600 | - | [85] | |
Death | 24; M | Apnea, Coma, Rattling breath, Hypothermia, Myosis, Tachycardia, Unconscious | Plasma 830 | U-4770 plasma 370 | [105] | |
Flubromazolam | ED | 27; M | Coma, Cyanosis, Hypotension, Unconscious, Respiratory depression, Tachycardia | Serum 59 Urine 105 | - | [106] |
20; M | Ataxia, Coma, Disorientation, Lethargy, Hallucinations, Hypotension, Miosis, Mydriasis, Seizures, Slurred speech, Tremor, Unconscious | Urine screen + | - | [74] | ||
18; F | Urine screen + | - | ||||
65; M | Urine screen + | - | ||||
26; M | Urine screen + | Meclonazepam urine screen + | ||||
15; F | Urine screen + | - | ||||
23; M | Urine screen + | - | ||||
49; M | Urine screen + | - | ||||
27; M | Urine screen + | - | ||||
20; F | Urine screen + | - | ||||
17; F | Urine screen + | - | ||||
17; F | Urine screen + | - | ||||
19; F | Urine screen + | - | ||||
23; M | Urine screen + | - | ||||
18; M | Urine screen + | Meclonazepam urine screen + | ||||
35; M | Urine screen + | - | ||||
18; M | Urine screen + | - | ||||
18; M | Urine screen + | - | ||||
DUID | 20, M | Mild impairment | Blood 0.48 | - | [85] | |
19; M | Considerable impairment | Blood 100 | - | |||
17; M | Driving impairment, Lethargy, Lack of balance, Slurred speech | Blood 17 | THC blood 6.1 | [71] | ||
18; M | Blood 18 | THC blood 2.2 | ||||
21; M | Blood 19 | BE blood 348 THC blood 1.5 | ||||
17; F | Blood 14 | EtOH blood 0.014 g/L | ||||
19; F | Blood 21 | COC blood screen + BE blood 749 | ||||
19; M | Blood 7 | CZP blood 7 7-Amino-CZP blood 26 OXY blood screen + THC blood 27 | ||||
22; F | Blood 12 | THC blood 2.9 | ||||
35; F | Blood 31 | THC blood 4.1 | ||||
21; F | Blood 8.2 | BE blood 356 THC blood 1 | ||||
Death | 34; M | Multiple drugs | Blood screen + | DZP blood 200 Nor-DZP blood 180 TMZ blood 11 MAMP blood screen + AMP blood 70 3-FPM blood 2.4, central blood 2.6 AMI blood 440 NTP blood 290 | [107] | |
39; M | Multiple drugs | Blood 70 | EtOH blood 0.24 g/L Etizolam blood 4 DZP blood 68 Nor-DZP blood 365 TMZ blood 6 OXZ blood 22 6-AM blood screen + MOR blood 1149 COD blood 289 COC blood 184 BE blood 525 CE blood 22 QTP blood 16 MIR blood 121 | [108] | ||
49; M | Blood 33 | Etizolam blood 1.5 DZP blood 89 Nor-DZP blood 575 OXZ blood 13 TMZ blood 5 MTD blood 685 EDDP blood 100 6-AM blood screen + MOR blood 73 COD blood 18 MIR blood 12 PGB blood 38.1 | ||||
33; F | Blood 1 | Etizolam blood 14 7-Amino-CZP blood screen + MOR blood 91 COC blood 46 BE blood 2573 CLO blood 2060 Nor-CLO blood 1629 GBP blood 24.6 LTG blood 5.8 PRO blood 186 | ||||
Self-administration | 44; M | Considerable impairment, delayed comprehension and reaction time, lethargy, muscle relaxation, partial amnesia, sedation | 0.5 mg oral ingestion Serum 7.4 (5 h) Serum 8.6 (8 h) Serum 5.2 (30 h) Hair 0.44 pg/mg (2 w) Hair 0.60 pg/mg (4 w) | BZD urine screen + | [109] | |
Meclonazepam | ED | 31; M | Agitation, Non-reactive pupils | Urine screen + | - | [74] |
Phenazepam | ED | 26; M | Ataxia, Lack of balance, Memory impairment, Slurred speech | Blood 1200 | BZD urine screen + VEN blood screen + | [110] |
42; M | Confusion, Disorientation, Mydriasis | Blood 490 | - | [111] | ||
29; M | Unresponsiveness, Tachycardia | Serum 1400 | BZD serum screen + U-47700 serum 240 | [112] | ||
Drug offense | 22 *; Not reported | Moderate motor impairment | Blood 260 | THC blood 0.7 | [86] | |
DUID | 50; F | Behavioral aberrations, Moderate/considerable functional disorders | Blood 270 | - | [113] | |
27; M | Blood 310 | - | ||||
21; M | Blood 3000 | - | ||||
47; F | Blood 230 | - | ||||
47; M | Blood 380 | - | ||||
18; M | Agitation, Amnesia, Disorientation, Lack of balance, Lethargy, Mydriasis, Myosis, Non-reactive pupils, Sedation, Slurred speech, Slow reactivity, Tachycardia | Blood 180 | THCCOOH blood 28 | [114] | ||
27; M | Blood 500 | CBP blood 6.1 | ||||
22; M | Blood 750 | TZD blood screen + | ||||
29; F | Blood 310 | AMP blood 190 QTP blood screen + | ||||
39; M | Blood 170 | THCCOOH urine screen + | ||||
23; M | Blood 140 | GBP blood screen + | ||||
22; M | Blood 3200 | - | ||||
40; M | Blood 40 | - | ||||
24; F | Blood 50 | - | ||||
29; M | Blood 120 | - | ||||
21; M | Blood 80 | - | ||||
24; M | Slurred speech, Lack of balance | Blood 76 | BZD blood screen + | [115] | ||
22 *; Not reported | Moderate impairment | Blood 170 | - | [86] | ||
42 *; Not reported | Mild impairment | Blood 12 | - | |||
Death | 42; M | Accidental death complicated by obesity and asthma, Multiple drugs | Blood 386 | MOR blood 116 COD blood 85, blood screen + HCOD urine screen + | [116] | |
35; M | Multiple drugs | Blood 220 | DZP blood 100 Nor-DZP blood 210 OXZ blood screen + TMZ blood screen + MTD blood 650, urine screen + EDDP blood screen + IBP blood screen + | [117] | ||
35; M | Blood 2520 | EtOH blood 0.06 g/L BZD blood and urine screen + MOR blood 360, urine screen + COD blood 380, urine screen + PAR blood and urine screen + | ||||
Not reported | Multiple drugs | Blood 960 | 3OH-Penazepam blood 230 DZP blood screen + Nor-DZP blood screen + TMZ blood screen + MOR blood 10 MOR-3-glucuronide blood 30 MOR-6-glucuronide blood 10 PRZ blood 500 | [118] | ||
Accidental overdose, Multiple drugs | Blood 960 | 3OH-Penazepam blood 270 DZP blood screen + Nor-DZP blood screen + DHC blood screen + DHC-6-glucuronide blood screen + NIC blood screen + | ||||
46; M | Phenazepam intoxication | Blood 1200 | EtOH blood 0.22 g/L | [119] | ||
26; M | Blood 1600 | DZP blood 160 DHC blood 160 | ||||
Not reported | Multiple drugs | Blood screen + | MTD blood 60 MOR blood 60 COC blood screen + AMI blood 80 GBP blood 30,000 | |||
Blood screen + | Etizolam blood 34 EtOH blood 2.9 g/L MOR blood screen + | |||||
Blood screen + | DZP blood 240 MTD blood 890 MOR blood 30 DHC blood 170 GBP blood 26,000 MIR blood 100 FLX blood 140 | |||||
Blood screen + | EtOH blood 3 g/L DZP blood 70 AMP blood 1500 | |||||
Blood 10 | MTD blood 770 | |||||
Blood 140 | EtOH blood 0.56 | |||||
Blood 20 | MTD blood 1300 | |||||
Blood 20 | EtOH blood 1.4 DZP blood screen + | |||||
Blood 24 | Etizolam blood 120 MTD blood 950 COD blood 60 AMI blood 990 | |||||
Blood 38 | DHC blood 1100 | |||||
Blood 40 | MTD blood 700 MOR blood 50 AMI blood 570 | |||||
Blood 40 | MTD blood 340 DZP blood 350 | |||||
Blood 40 | MTD blood 390 | |||||
Blood 43 | DZP blood 510 MTD blood 900 MOR blood screen + MIR blood 580 | |||||
Blood 45 | Etizolam blood 73 DHC blood 300 GBP blood 42000 | |||||
Blood 50 | DZP blood 450 MOR blood 450 | |||||
Blood 60 | EtOH blood 0.79 g/L BUP blood 5 AMI blood 70 | |||||
Blood 60 | MTD blood 410 | |||||
Blood 67 | Etizolam blood 380 MOR blood 170 | |||||
Blood 80 | MTD blood 290 | |||||
Blood 80 | Etizolam blood screen + DZP blood screen + MOR blood 590 | |||||
Blood 80 | MTD blood 770 MOR blood 10 | |||||
Blood 80 | Etizolam blood screen + DZP blood screen + MOR blood 590 | |||||
Blood 90 | MOR blood 310 | |||||
Blood 90 | MOR blood 560 | |||||
Blood 100 | MTD blood 590 MOR blood 40 | |||||
Blood 100 | MTD blood 130 DOT blood 580 | |||||
Blood 100 | MTD blood 1200 BEG v blood screen + | |||||
Blood 100 | MTD blood 280 DHC blood 1600 | |||||
Blood 110 | MTD blood 540 MOR blood 40 BEG blood screen + | |||||
Blood 110 | OLZ blood 420 ZPC blood 10 | |||||
Blood 110 | EtOH blood 1.6 g/L BUP blood screen + | |||||
Blood 110 | MTD blood 270 | |||||
Blood 120 | FEN blood 55 TMD blood 1400 DOT blood 3300 GBP blood 23,000 | |||||
Blood 160 | DZP blood 980 MOR blood 430 BEG blood screen + | |||||
Blood 200 | MOR blood 360 DHC blood 990 | |||||
Blood 210 | MTD blood 180 | |||||
Blood 240 | MTD blood 390 MIR blood 60 | |||||
Blood 240 | DZP blood 350 MTD blood 340 | |||||
Blood 240 | MTD blood 510 AMI blood 840 | |||||
Blood 260 | MTD blood 240 COD blood 1100 | |||||
Blood 280 | EtOH blood 3.1 g/L | |||||
Blood 280 | MTD blood 250 PGB blood 8000 | |||||
Blood 330 | MTD blood 750 MOR blood 330 GBP blood 103000 | |||||
Blood 330 | EtOH blood 2.5 g/L Nor-BUP blood 13 | |||||
Blood 460 | MTD blood screen + | |||||
Blood 550 | EtOH blood 3.3 g/L | |||||
Blood 640 | MTD blood 1100 | |||||
Blood 820 | MTD blood 470 | |||||
Blood 900 | DZP blood 120 MTD blood 380 DHC blood 730 AMP blood 110 | |||||
Blood 1700 | DHC blood 4400 | |||||
Blood 1700 | MOR blood 50 | |||||
Blood screen + | DZP blood 170 TMD blood 7800 DHC blood 220 | |||||
Pyrazolam | Death | 27; M | Multiple drugs | Blood 28 Central blood 28 Urine 500 | Diclazepam blood 1, central blood 1, urine 1 DLP blood 100, central blood 250, urine 570 LMZ blood 6, central blood 4, urine 810 LZP blood 22, central blood 22, urine 820 3-FPM blood 10, central blood 9, urine 120 2F-MAMP urine 120 2F-AMP blood 89 MPA blood 2.2, urine 16 AMP blood 21, urine 75 DPH urine 340 | [120] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Brunetti, P.; Giorgetti, R.; Tagliabracci, A.; Huestis, M.A.; Busardò, F.P. Designer Benzodiazepines: A Review of Toxicology and Public Health Risks. Pharmaceuticals 2021, 14, 560. https://doi.org/10.3390/ph14060560
Brunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP. Designer Benzodiazepines: A Review of Toxicology and Public Health Risks. Pharmaceuticals. 2021; 14(6):560. https://doi.org/10.3390/ph14060560
Chicago/Turabian StyleBrunetti, Pietro, Raffaele Giorgetti, Adriano Tagliabracci, Marilyn A. Huestis, and Francesco Paolo Busardò. 2021. "Designer Benzodiazepines: A Review of Toxicology and Public Health Risks" Pharmaceuticals 14, no. 6: 560. https://doi.org/10.3390/ph14060560
APA StyleBrunetti, P., Giorgetti, R., Tagliabracci, A., Huestis, M. A., & Busardò, F. P. (2021). Designer Benzodiazepines: A Review of Toxicology and Public Health Risks. Pharmaceuticals, 14(6), 560. https://doi.org/10.3390/ph14060560